{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T17:58:06Z","timestamp":1791136686984,"version":"4.1.0"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,3,27]]},"DOI":"10.1097\/tp.0b013e31827e6ad9","type":"journal-article","created":{"date-parts":[[2013,5,23]],"date-time":"2013-05-23T19:45:43Z","timestamp":1369338343000},"page":"821-827","source":"Crossref","is-referenced-by-count":32,"title":["CYP3A5 Gene Variation Influences Cyclosporine A Metabolite Formation and Renal Cyclosporine Disposition"],"prefix":"10.1097","volume":"95","author":[{"given":"Songmao","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasar","family":"Tasnif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary F.","family":"Hebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie L.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihisa","family":"Shitara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justina C.","family":"Calamia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne S.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny D.","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth E.","family":"Thummel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210129","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/S0140-6736(78)91970-0","article-title":". Cyclosporin A in patients receiving renal allografts from cadaver donors.","volume":"2","author":"Calne","year":"1978","journal-title":"Lancet"},{"key":"R2-7-20210129","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S0140-6736(81)91851-1","article-title":"Nephrotoxicity of cyclosporin A in liver and kidney transplant patients.","volume":"1","author":"Klintmalm","year":"1981","journal-title":"Lancet"},{"key":"R3-7-20210129","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJM198409133111103","article-title":". Cyclosporine-associated chronic nephropathy.","volume":"311","author":"Myers","year":"1984","journal-title":"N Engl J Med"},{"key":"R4-7-20210129","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1056\/NEJMoa020009","article-title":". The natural history of chronic allograft nephropathy.","volume":"349","author":"Nankivell","year":"2003","journal-title":"N Engl J Med"},{"key":"R5-7-20210129","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1097\/TP.0b013e31824db954","article-title":"The bumpy road of genomic medicine in transplantation: lessons from studies on calcineurin inhibitor nephrotoxicity.","volume":"93","author":"Naesens","year":"2012","journal-title":"Transplantation"},{"key":"R6-7-20210129","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity.","volume":"4","author":"Naesens","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R7-7-20210129","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0163-7258(93)90059-M","article-title":"Cyclosporin metabolism in transplant patients.","volume":"57","author":"Christians","year":"1993","journal-title":"Pharmacol Ther"},{"key":"R8-7-20210129","first-page":"1315","article-title":". Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability.","volume":"23","author":"Lampen","year":"1995","journal-title":"Drug Metab Dispos"},{"key":"R9-7-20210129","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1124\/mol.62.1.162","article-title":". Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism.","volume":"62","author":"Lin","year":"2002","journal-title":"Mol Pharmacol"},{"key":"R10-7-20210129","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86882","article-title":". Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression.","volume":"27","author":"Kuehl","year":"2001","journal-title":"Nat Genet"},{"key":"R11-7-20210129","first-page":"52","article-title":". Bimodal distribution of renal cytochrome P450 3A activity in humans.","volume":"50","author":"Haehner","year":"1996","journal-title":"Mol Pharmacol"},{"key":"R12-7-20210129","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1152\/japplphysiol.00322.2003","article-title":". CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults.","volume":"95","author":"Givens","year":"2003","journal-title":"J Appl Physiol"},{"key":"R13-7-20210129","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/j.bcp.2004.07.012","article-title":". In vitro metabolism of cyclosporine A by human kidney CYP3A5.","volume":"68","author":"Dai","year":"2004","journal-title":"Biochem Pharmacol"},{"key":"R14-7-20210129","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2165\/11317350-000000000-00000","article-title":"Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part I.","volume":"49","author":"Staatz","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"R15-7-20210129","first-page":"614","article-title":"Deposition of nine metabolites of cyclosporine in human tissues, bile, urine, and whole blood.","volume":"20","author":"Lensmeyer","year":"1988","journal-title":"Transplant Proc"},{"key":"R16-7-20210129","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0169-409X(97)00043-4","article-title":"Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery.","volume":"27","author":"Hebert","year":"1997","journal-title":"Adv Drug Deliv Rev"},{"key":"R17-7-20210129","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/j.transproceed.2005.03.149","article-title":". Determination of cyclosporine and its metabolites in blood via HPLC-MS and correlation to clinically important parameters.","volume":"37","author":"Vollenbroeker","year":"2005","journal-title":"Transplant Proc"},{"key":"R18-7-20210129","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF00314953","article-title":". Ciclosporin metabolite pattern in blood and urine of liver graft recipients. I. Association of ciclosporin metabolites with nephrotoxicity.","volume":"41","author":"Christians","year":"1991","journal-title":"Eur J Clin Pharmacol"},{"key":"R19-7-20210129","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/S0041-1345(01)01929-7","article-title":". Cyclosporine A metabolite AM19 as a potential biomarker in urine for CSA nephropathy.","volume":"33","author":"Kempkes-Koch","year":"2001","journal-title":"Transplant Proc"},{"key":"R20-7-20210129","first-page":"1135","article-title":"Studies of cyclosporine and metabolite toxicity in renal and hepatocyte culture systems.","volume":"22","author":"Bowers","year":"1990","journal-title":"Transplant Proc"},{"key":"R21-7-20210129","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/00007691-199011000-00003","article-title":"Toxicity of cyclosporine metabolites.","volume":"12","author":"Copeland","year":"1990","journal-title":"Ther Drug Monit"},{"key":"R22-7-20210129","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/00007890-199203000-00028","article-title":"Comparison of the effects of cyclosporine and its metabolites on the release of prostacyclin and endothelin from mesangial cells.","volume":"53","author":"Copeland","year":"1992","journal-title":"Transplantation"},{"key":"R23-7-20210129","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.transproceed.2005.01.077","article-title":". Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus.","volume":"37","author":"Zhao","year":"2005","journal-title":"Transplant Proc"},{"key":"R24-7-20210129","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.transproceed.2008.04.010","article-title":". Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients.","volume":"40","author":"Loh","year":"2008","journal-title":"Transplant Proc"},{"key":"R25-7-20210129","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0009-9236(03)00168-1","article-title":". Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus.","volume":"74","author":"Hesselink","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"R26-7-20210129","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.clpt.2004.01.009","article-title":". CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation.","volume":"75","author":"Anglicheau","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"R27-7-20210129","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/00007691-200410000-00010","article-title":". CYP3A5 polymorphism and the ethnic differences in cyclosporine pharmacokinetics in healthy subjects.","volume":"26","author":"Min","year":"2004","journal-title":"Ther Drug Monit"},{"key":"R28-7-20210129","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/00008571-200403000-00002","article-title":". The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients.","volume":"14","author":"Haufroid","year":"2004","journal-title":"Pharmacogenetics"},{"key":"R29-7-20210129","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1097\/01.TP.0000121133.84763.26","article-title":"AE, Sobh MA, Hamdy AF, et al.. A prospective, randomized study of coadministration of ketoconazole and cyclosporine a in kidney transplant recipients: ten-year follow-up.","volume":"77","year":"2004","journal-title":"Transplantation"},{"key":"R30-7-20210129","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/00007691-199708000-00013","article-title":". Ketoconazole and fluconazole inhibition of the metabolism of cyclosporin A by human liver in vitro.","volume":"19","author":"Omar","year":"1997","journal-title":"Ther Drug Monit"},{"key":"R31-7-20210129","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1038\/sj.ki.5000325","article-title":". The influence of CYP3A gene polymorphisms on cyclosporine dose requirement in renal allograft recipients.","volume":"69","author":"Eng","year":"2006","journal-title":"Kidney Int"},{"key":"R32-7-20210129","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.healun.2008.04.001","article-title":". No association between single nucleotide polymorphisms and the development of nephrotoxicity after orthotopic heart transplantation.","volume":"27","author":"Klauke","year":"2008","journal-title":"J Heart Lung Transplant"},{"key":"R33-7-20210129","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1681\/ASN.2004100882","article-title":". ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation.","volume":"16","author":"Hauser","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R34-7-20210129","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/sj.tpj.6500488","article-title":". CYP3A5 genotype is associated with longer patient survival after kidney transplantation and long-term treatment with cyclosporine.","volume":"8","author":"Kreutz","year":"2008","journal-title":"Pharmacogenomics J"},{"key":"R35-7-20210129","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.healun.2010.09.015","article-title":". Association between renal function and CYP3A5 genotype in heart transplant recipients treated with calcineurin inhibitors.","volume":"30","author":"de Denus","year":"2011","journal-title":"J Heart Lung Transplant"},{"key":"R36-7-20210129","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2165\/11317550-000000000-00000","article-title":"Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part II.","volume":"49","author":"Staatz","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"R37-7-20210129","first-page":"931","article-title":"Inhibition of esterolysis of enalapril by paraoxon increases the urinary clearance in isolated perfused rat kidney.","volume":"27","author":"Sirianni","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"R38-7-20210129","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/clpt.2012.175","article-title":". Measurement and compartmental modeling of the effect of CYP3A5 gene variation on systemic and intrarenal tacrolimus disposition.","volume":"92","author":"Zheng","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"R39-7-20210129","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/00008571-200311000-00002","article-title":". Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors.","volume":"13","author":"Hebert","year":"2003","journal-title":"Pharmacogenetics"},{"key":"R40-7-20210129","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/00008571-200311000-00003","article-title":". ABCB1 C3435T and G2677TA polymorphism decreased the risk for steroid-induced osteonecrosis of the femoral head after kidney transplantation.","volume":"13","author":"Asano","year":"2003","journal-title":"Pharmacogenetics"},{"key":"R41-7-20210129","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/clpt.2008.1","article-title":". Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study.","volume":"84","author":"Hebert","year":"2008","journal-title":"Clin Pharmacol Ther"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0b013e31827e6ad9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T07:30:43Z","timestamp":1620977443000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007890-201303270-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,27]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0b013e31827e6ad9","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3,27]]}}}